C-Reactive Protein in Various Degrees Severity of Psoriasis Vulgaris

Background: Psoriasis vulgaris is an inflammatory, chronic, recurrent, and, non-contangious skin disease. The severity grade of psoriasis is measured with p soriasis a rea and s everity i ndex (PASI) score. C-reactive protein (CRP) is a sensitive, but not specific indicator of inflammation. In the active stage of psoriasis, highly increased CRP levels were found, whereas at remission they present a decrease level. Purpose: To evaluate the profile of CRP level in psoriasis vulgaris patients with various degress of psoriasis vulgaris severity in Dr. Soetomo Hospital Surabaya. Methods: Blood samples were collected in 16 patients to measure the CRP level in psoriasis vulgaris patients with various degrees of severity. Results: There were 16 patients (10 male and 6 female) with various degrees of psoriasis vulgaris severity (5 patients with mild severity, 8 patients with moderate severity, and 3 patients with severe severity). All CRP  results  were within normal limits . Conclusion: Many factors can influence the CRP levels, CRP can not be  as single  indicator of inflammation in psoriasis vulgaris. Key words: psoriasis vulgaris, c-reactive protein, PASI score.

[1]  W. James,et al.  Andrews' Diseases of the skin: Clinical dermatology , 2014 .

[2]  Yu-Huei Huang,et al.  Efficacy and safety of etanercept in the treatment of recalcitrant psoriasis: An open-label, retrospective, observational study in Taiwan , 2013 .

[3]  I. Flytström.  Different aspects of psoriasis etiology and treatment , 2012 .

[4]  S. Coimbra,et al.  Psoriasis: Epidemiology, Clinical and Histological Features, Triggering Factors, Assessment of Severity and Psychosocial Aspects , 2012 .

[5]  Isha,et al.  C-Reactive Protein and Uric Acid Levels in Patients with Psoriasis , 2011, Indian Journal of Clinical Biochemistry.

[6]  L. Manolache,et al.  Life events involvement in psoriasis onset/recurrence , 2010, International journal of dermatology.

[7]  E. Liberopoulos,et al.  High-Sensitivity C-Reactive Protein: To Measure or not to Measure?~!2009-10-29~!2009-12-22~!2010-04-08~! , 2010 .

[8]  L. Belo,et al.  C‐reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[9]  D. Burden,et al.  C‐reactive protein in psoriasis , 2007, The British journal of dermatology.

[10]  L. Naldi,et al.  The clinical spectrum of psoriasis. , 2007, Clinics in dermatology.

[11]  Jochen Schmitt,et al.  The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis , 2005, Dermatology.

[12]  S. Feldman,et al.  Psoriasis assessment tools in clinical trials , 2005, Annals of the rheumatic diseases.

[13]  G. Chodorowska,et al.  C‐reactive protein and α2‐macroglobulin plasma activity in medium–severe and severe psoriasis , 2004, Journal of the European Academy of Dermatology and Venereology : JEADV.

[14]  A. Gautier,et al.  C-reactive protein , 2005 .

[15]  S. Sandhu,et al.  CLINICAL EVALUATION OF DIFFERENT THERAPEUTIC MODALITIES IN PSORIASIS BY PASI SCORE , 2012 .

[16]  Sudaryanto Sudaryanto,et al.  Hubungan Derajat Keparahan Psoriasis Vulgaris Terhadap Kualitas Hidup Penderita , 2012 .

[17]  K. Asadullah,et al.  Cytokine and Anti-Cytokine Therapies for Psoriasis and Atopic Dermatitis , 2012, BioDrugs.

[18]  B. Thiers.  Psoriasis and the risk of incident diabetes mellitus: a population-based study , 2009 .

[19]  I. Rebelo,et al.  Clinical and Laboratory Investigations The inflammatory response in mild and in severe psoriasis , 2004 .